Effect of fixed dose combinations of different α1-blockers with dutasteride on quality of life in patients of lower urinary tract symptoms with benign prostatic hyperplasia


  • Nishant Madan Department of Pharmacology, Pt. BD Sharma PGIMS, Rohtak, Haryana, India
  • M. C. Gupta Department of Pharmacology, Pt. BD Sharma PGIMS, Rohtak, Haryana, India
  • Hemant Kamal Department of Urology, Pt. BD Sharma PGIMS, Rohtak, Haryana, India




Benign prostatic hyperplasia, Dutasteride, Fixed dose combinations, Lower urinary tract symptoms, Quality of life, α1-blockers


Background: Fixed dose combination (FDC’s) of α1-blockers and 5α-reductase inhibitors have commonly been used in patients with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). This study compared the effect of FDC’s of tamsulosin, alfuzosin and silodosin with dutasteride on quality of life (QoL) in patients of LUTS with BPH.

Methods: Ninety-six male patients aged ≥45 years diagnosed with LUTS and BPH were randomized to receive FDC’s of dutasteride with tamsulosin (group 1), alfuzosin (group 2) and silodosin (group 3) over a period of 16 weeks. Quality of life was assessed using International Prostate Symptom Score (IPSS) 8th question, BPH impact index (BII) and modified Patient Perception of Study Medication (PPSM) questionnaire.

Results: IPSS 8th question score improved significantly by 61.68%, 57.63% and 63.4% in group 1, 2 and 3 respectively. BPH Impact Index score also improved significantly by 62.95%, 60.13% and 61.82% in group 1, 2 and 3 respectively. All the three treatments were found to be similar in improving the QoL. Majority of patients were satisfied with their treatment and wanted to receive the medication again while a small number of patients were neutral with the study medication. None of the subjects was dissatisfied with any of the treatment.

Conclusions: All the FDC’s improved QoL and were found to be satisfactory as per patient perception of study medications.


Stroup SP, Palazzi-Churas K, Kopp RP, Parsons JK. Trends in adverse events of benign prostatic hyperplasia (BPH) in the USA, 1998 to 2008. BJU Int. 2012;109:84-7.

Scher HI, Eastham JA. Benign and Malignant Diseases of the Prostate. In: Kasper DL, Fausi AS, Hauser SL, Longo DL, Jameson JL, Loscalzo J, editors. Harrison’s Principles of Internal Medicine. 19th ed. New York: McGraw-Hill; 2015: 579-87.

Kupelian V, Wei JT, O’Leary MP, Kusek JW, Litman HJ, Link CL, et al. Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample. The Boston Area Community Health (BACH) Survey. Arch Intern Med. 2006;166:2381-7.

Taylor BC, Wilt TJ, Fink HA, Lambert LC, Marshall LM, Hoffman AR, et al. Prevalence, severity, and health correlates of lower urinary tract symptoms among older men: The MrOS study. Urol. 2006;68:804-9.

Girman CJ, Jacobsen SJ, Rhodes T, Guess HA, Roberts RO, Lieber MM. Association of health-related quality of life and benign prostatic enlargement. Eur Urol. 1999;35:277-84.

Parsons JK, Mougey J, Lambert L, Wilt TJ, Fink HA, Garzotto M, et al. Lower urinary tract symptoms increase the risk of falls in older men. BJU Int. 2009;104:63-8.

Sountoulides P, Dijk MM, Wijkstra H, Rosette JJ, Michel MC. Role of voiding and storage symptoms for the quality of life before and after treatment in men with voiding dysfunction. World J Urol. 2010;28:3-8.

Rosenberg MT, Witt ES, Miner M, Barkin J. A practical primary care approach to lower urinary tract symptoms caused by benign prostate hyperplasia (BPH-LUTS). Can J Urol. 2014;21(2):12-24.

Boyle P, Roehrborn C, Harkaway R, Logie J, de la Rosette J, Emberton M. 5-Alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery. Eur Urol. 2004;45:620-6.

Badia X, Garcia-Losa M, Dal-Re R. Ten-language translation and harmonisation of the international prostate symptom score: developing a methodology for multinational clinical trials. Eur Urol. 1997;31:129-40.

Kingery L, Martin ML, Naegeli AN, Khan S, Viktrup L. Content validity of the Benign Prostatic Hyperplasia Impact Index (BII); a measure of how urinary trouble and problems associated with BPH may impact the patient. Int J Clin Pract. 2012;66(9):883-90.

Black L, Grove A, Morrill B. The psychometric validation of a US English satisfaction measure for patients with benign prostatic hyperplasia and lower urinary tract symptoms. Health Qual Life Outcomes. 2009;7:55.

Barkin J, Roehrborn CG, Siami P, Haillot O, Morrill B, Black L, et al. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial. BJU Int. 2009;103:919-26.

Roehrborn CG, Perez IO, Roos EPM, Calomfirescu N, Brotherton B, Wang F, et al. Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart®) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naïve men with moderately symptomatic benign prostatic hyperplasia: 2-year Conduct study results. BJU Int. 2015;116:450-9.

Chung BH, Roehrborn CG, Siami P, Major-Walker K, Morrill BB, Wilson TH, et al. Efficacy and safety of dutasteride, tamsulosin and their combination in a subpopulation of the CombAT study: 2-year results in Asian men with moderate-to-severe BPH. Prostate Cancer Prostatic Dis. 2009;12:152-9.




How to Cite

Madan, N., Gupta, M. C., & Kamal, H. (2019). Effect of fixed dose combinations of different α1-blockers with dutasteride on quality of life in patients of lower urinary tract symptoms with benign prostatic hyperplasia. International Journal of Basic & Clinical Pharmacology, 8(6), 1248–1253. https://doi.org/10.18203/2319-2003.ijbcp20192184



Original Research Articles